[HTML][HTML] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised …

HM Earl, L Hiller, AL Vallier, S Loi, K McAdam… - The Lancet, 2019 - thelancet.com
Background Adjuvant trastuzumab significantly improves outcomes for patients with HER2-
positive early breast cancer. The standard treatment duration is 12 months but shorter …

[HTML][HTML] Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with …

HM Earl, AL Vallier, L Hiller, N Fenwick, J Young… - The lancet …, 2014 - thelancet.com
Background Anthracyclines and taxanes have been the standard neoadjuvant
chemotherapies for breast cancer in the past decade. We aimed to assess safety and …

[HTML][HTML] Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early …

HM Earl, L Hiller, JA Dunn, C Blenkinsop… - The lancet …, 2015 - thelancet.com
Summary Background The ARTemis trial was developed to assess the efficacy and safety of
adding bevacizumab to standard neoadjuvant chemotherapy in HER2-negative early breast …

[PDF][PDF] Combined point-of-care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G spike variant

P Mlcochova, D Collier, A Ritchie, SM Assennato… - Cell Reports …, 2020 - cell.com
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%–
50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing …

Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel

JE Abraham, Q Guo, L Dorling, J Tyrer, S Ingle… - Clinical Cancer …, 2014 - AACR
Purpose: Associations between taxane-related sensory neuropathy (TRSN) and single-
nucleotide polymorphisms (SNP) have previously been reported, but few have been …

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non …

HM Earl, L Hiller, AL Vallier, S Loi, D Howe, HB Higgins… - 2018 - ascopubs.org
506 Background: Adjuvant trastuzumab has significantly improved outcomes for HER2+
EBC pts, using the 12m duration empirically adopted from the pivotal registration trials. A …

[HTML][HTML] Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

HR Ali, A Dariush, E Provenzano, H Bardwell… - Breast Cancer …, 2016 - Springer
Background There is a need to improve prediction of response to chemotherapy in breast
cancer in order to improve clinical management and this may be achieved by harnessing …

[HTML][HTML] Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary …

HR Ali, A Dariush, J Thomas, E Provenzano, J Dunn… - Annals of …, 2017 - Elsevier
Background We have previously shown lymphocyte density, measured using computational
pathology, is associated with pathological complete response (pCR) in breast cancer. The …

[HTML][HTML] Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes–what does it all mean?

H Earl, E Provenzano, J Abraham, J Dunn, AL Vallier… - BMC medicine, 2015 - Springer
Background Neoadjuvant breast cancer trials are important for speeding up the introduction
of new treatments for patients with early breast cancer and for the highly productive …

[HTML][HTML] Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for …

HM Earl, L Hiller, JA Dunn, C Blenkinsop… - Annals of …, 2017 - Elsevier
ABSTRACT Background The ARTemis trial previously reported that addition of neoadjuvant
bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and …